Anna-Maria Langkilde
University Medical Center Groningen
3 papers in the Anchorcite directory, published between 2018 and 2020, cited 20,121 times in total.
Research topics
- Diabetes Treatment and Management · 3 papers
- Heart Failure Treatment and Management · 2 papers
- Chronic Kidney Disease and Diabetes · 2 papers
- Cardiovascular Function and Risk Factors · 1 paper
- Acute Kidney Injury Research · 1 paper
Frequent co-authors
- John J.V. McMurray · 2 papers
- Marc Steven Sabatine · 2 papers
- Scott David Solomon · 1 paper
- Silvio E. Inzucchi · 1 paper
- Lars Køber · 1 paper
- Mikhail Kosiborod · 1 paper
- Felipe A. Martínez · 1 paper
- Piotr P. Ponikowski · 1 paper
Papers
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine · 2019 · 7,529 citations
BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with…
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine · 2018 · 6,600 citations
BACKGROUND: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS: of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes)…
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine · 2020 · 5,992 citations
BACKGROUND: Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known. METHODS: of body-surface area and…
Metadata from OpenAlex (CC0).